Summary: In a multicentre trial in diabetes-free people with obesity and fatty liver disease, berberine 1 g/day for 6 months did not reduce visceral fat or liver fat compared with placebo, though it modestly lowered LDL cholesterol, apolipoprotein B, and an inflammatory marker.
PICO Summary
| Element | Detail |
|---|---|
| Population | 337 diabetes-free adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD); multicentre, double-blind randomised trial at 11 hospitals, China. |
| Intervention | Oral berberine 1 g/day for 6 months (n=169). |
| Comparison | Matching placebo (n=168). |
| Outcome | No significant difference in the co-primary endpoints of visceral adipose tissue area (1.4%; 97.5% CI -2.4 to 5.2) or liver fat content (0.9%; 97.5% CI -0.4 to 2.1). Berberine produced modest reductions in LDL cholesterol (-7.72 mg/dL), apolipoprotein B (-3.42 mg/dL), and hs-CRP (-0.072 mg/dL), but not other secondary outcomes. Adverse events were similar between arms. |
Berberine for visceral and liver fat in obesity with MASLD
RCT · obesity with MASLD · 6 months
Berberine 1 g/day for 6 months did not reduce visceral or liver fat versus placebo; both co-primary endpoints crossed no effect. It modestly lowered LDL, apoB, and hs-CRP.
Expert Commentary
This is the most rigorous test to date of a heavily marketed claim, and it is decisively negative on the endpoints that matter most for the marketing. Berberine, widely promoted as a natural agent that melts visceral and liver fat, did neither over six months in a well-powered, double-blind, multicentre trial with imaging-based endpoints, with confidence intervals comfortably spanning no effect. That null is the headline and should be reported as such. The secondary findings are real but modest and mechanistically unsurprising, a small LDL and apolipoprotein B reduction and a slight fall in hs-CRP, consistent with prior meta-analyses of berberine’s lipid effect, but they do not rescue the primary hypothesis. The limitations the post fairly notes include a Chinese-only population, a six-month window that might miss slower fat changes, exclusion of people with diabetes who might respond differently, imperfectly monitored lifestyle compliance, and a single dose. Can I use this with my patients? Yes, to counsel honestly. I would tell patients berberine is not an evidence-based treatment for belly fat or fatty liver and redirect them to proven lifestyle measures, while acknowledging that its small lipid-lowering effect might, through shared decision-making, have a niche adjunctive role in dyslipidaemia for those who cannot take statins, as an off-label choice.
References
Lei L, Wang B, Zhao L, et al. Berberine and adiposity in diabetes-free individuals with obesity and MASLD: a randomized clinical trial. JAMA Netw Open. 2026;9(1):e2554152. doi:10.1001/jamanetworkopen.2025.54152